FDA Warns of Increased Cardiovascular and Cancer Risks with JAK Inhibitors in Rheumatoid Arthritis

Executive Brief

News Report

The News: FDA warns of increased cardiovascular and cancer risks with JAK inhibitors for rheumatoid arthritis.
Clinical Win: Clinicians must carefully evaluate the risk-benefit profile of JAK inhibitors in RA patients.
Target Specialty: Rheumatology

Key Data at a Glance

Increased cardiovascular events: Higher incidence with JAK inhibitors compared to TNF inhibitors
Cancer risk: Increased risk associated with JAK inhibitors

The FDA has issued a warning regarding Janus kinase (JAK) inhibitors, including tofacitinib (Xeljanz), baricitinib (Olumiant), and upadacitinib (Rinvoq), highlighting an increased risk of serious cardiovascular events and malignancies in patients with rheumatoid arthritis. This alert is significant for healthcare providers as it necessitates careful patient selection and monitoring when prescribing these therapies.

Clinical Context

Rheumatoid arthritis (RA) is a chronic autoimmune disorder affecting approximately 18 million people worldwide, predominantly women over the age of 55 [3]. It leads to joint inflammation, pain, and potential disability if not adequately managed. Current treatment strategies often include disease-modifying antirheumatic drugs (DMARDs) such as TNF inhibitors (e.g., infliximab, etanercept) and newer biologics like JAK inhibitors. While these therapies can effectively reduce disease activity and improve quality of life, they may also carry risks of serious adverse events, including cardiovascular complications and malignancies [4]. The recent FDA warning underscores the importance of evaluating the risk-benefit profile of these medications, particularly in patients with existing cardiovascular risk factors or a history of cancer.

Key Findings

The FDA has mandated updates to the boxed warnings for JAK inhibitors, including tofacitinib, baricitinib, and upadacitinib, to reflect the increased risk of serious heart-related events, cancer, blood clots, and death [5].

A large randomized safety trial comparing tofacitinib with TNF inhibitors revealed a higher incidence of cardiovascular events and malignancies in patients treated with JAK inhibitors [4].

The trial data indicated that patients on tofacitinib had an increased risk of heart attack and stroke compared to those receiving TNF blockers, prompting the need for careful monitoring of cardiovascular health in patients prescribed these therapies [5].

The FDA's review of these medications also noted that while baricitinib and upadacitinib have not been studied in similar safety trials, they share mechanisms of action with tofacitinib and may present similar risks [5].

What This Means for Clinical Practice

Healthcare providers must exercise caution when prescribing JAK inhibitors for rheumatoid arthritis, particularly in patients with pre-existing cardiovascular conditions or a history of malignancies. Clinicians should engage in thorough discussions with patients regarding the risks associated with these treatments and consider alternative therapies, such as TNF inhibitors, especially in high-risk populations. Regular cardiovascular assessments and monitoring for signs of malignancy should be integrated into the management plan for patients receiving JAK inhibitors to mitigate potential adverse outcomes. As the landscape of RA treatment evolves, understanding the implications of these safety warnings will be crucial in optimizing patient care and outcomes.

Clinical Perspective

Workflow: Clinicians should integrate regular cardiovascular assessments into the management of RA patients on JAK inhibitors.

Economics: The increased risk of serious adverse events may lead to higher healthcare costs due to additional monitoring and treatment.

Patient Outcomes: Understanding the risks associated with JAK inhibitors is essential for optimizing patient safety and treatment efficacy.

Dr. Deepak Nair, Rheumatology

FDA Warns of Increased Cardiovascular and Cancer Risks with JAK Inhibitors in Rheumatoid Arthritis

Executive Brief

Key Data at a Glance

Clinical Context

Key Findings

What This Means for Clinical Practice

Clinical Perspective

References

Get weekly drug updates for Rheumatology in your inbox.

Related Drug Updates

FDA Approves Deucravacitinib for Psoriatic Arthritis: TYK2 Inhibition Reduces Disease Activity

Deucravacitinib vs IL-17 and IL-23 Inhibitors: A Comparison for Psoriatic Arthritis Management

Verified HCP Portal